← Eichor
Condition: Kras Mutant Colorectal Cancer Crc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Kras Mutant Colorectal Cancer Crc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108
Phase 3 · 217 location(s) · Merck Sharp & Dohme LLC · NCT06997497A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorec
Phase 1 · 3 location(s) · University of Southern California · NCT06336902A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/Phase 2 · 32 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06959615Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or W
Phase 2 · 1 location(s) · Zhejiang University · NCT07581912KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06411691TCR1188-ABC Cells in KRAS-mutated Cancers
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07594067JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/Phase 2 · 4 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06973564MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · 52 location(s) · Eli Lilly and Company · NCT06586515BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 · 17 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06917079Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Phase 1 · 9 location(s) · Revolution Medicines, Inc. · NCT07349537Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherap
Phase 1/Phase 2 · 4 location(s) · Auricula Biosciences Inc. · NCT07148128Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · 17 location(s) · Revolution Medicines, Inc. · NCT06040541A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral On
Phase 1 · 9 location(s) · Kestrel Therapeutics, Inc. · NCT07458347
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.